Results of Antibiotic Susceptibility Testing Do Not Influence Clinical Outcome in Children with Cystic Fibrosis

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2012 Mar 23

PMID 22436723

Citations 55

Authors

M N Hurley

A H Amin Ariff

C Bertenshaw

J Bhatt

A R Smyth

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with CF experience pulmonary exacerbations. These are often initially empirically treated with intravenous antibiotics, with antibiotic choice refined after susceptibility testing.

Methods: We completed a 5-year retrospective review of children attending the Paediatric CF Unit, Nottingham. The respiratory sampling, antibiotic prescribing and susceptibility testing guidance were audited. Episodes were classified according to the concordance between the antibiotics prescribed and antibiotic susceptibility testing.

Results: Of 52 patients who had previously isolated Pseudomonas aeruginosa, 103 antibiotic courses were commenced that coincided with an isolation of P. aeruginosa. P. aeruginosa was fully susceptible, partially susceptible or fully resistant on 33%, 44.7% or 16.5% of occasions respectively. The antibiotic prescriptions were never changed following antibiotic susceptibility testing. We found no association between change in FEV(1) (p=0.54), change in BMI (p=0.12) or time to next exacerbation (p=0.66) and concordance between antibiotic susceptibility and the antibiotics administered.

Conclusion: This study contributes to mounting evidence questioning the utility of routine antibiotic susceptibility testing.

Citing Articles

The antimicrobial potential of traditional remedies of Indigenous peoples from Canada against MRSA planktonic and biofilm bacteria in wound infection mimetic conditions.

Rieger C, Soliman A, Kaplia K, Ghosh N, Lopez A, Venkatesan S Microbiol Spectr. 2024; :e0234124.

PMID: 39530700 PMC: 11619235. DOI: 10.1128/spectrum.02341-24.

Impact of Growth Conditions on High-Throughput Identification of Repurposing Drugs for Cystic Fibrosis Lung Infections.

Di Bonaventura G, Lupetti V, Pompilio A Antibiotics (Basel). 2024; 13(7).

PMID: 39061324 PMC: 11273527. DOI: 10.3390/antibiotics13070642.

Case Report: The Conundrum of What to Pick? Antibiotic Susceptibility Variability in in Cystic Fibrosis: Implications for Antibiotic Susceptibility Testing and Treatment.

Moore J, McCaughan J, Rendall J, Millar B Br J Biomed Sci. 2024; 81:12749.

PMID: 38895586 PMC: 11182986. DOI: 10.3389/bjbs.2024.12749.

Pf bacteriophages hinder sputum antibiotic diffusion via electrostatic binding.

Chen Q, Cai P, Chang T, Burgener E, Kratochvil M, Gupta A Sci Adv. 2024; 10(22):eadl5576.

PMID: 38820163 PMC: 11141622. DOI: 10.1126/sciadv.adl5576.

Mucus polymer concentration and adaptation converge to define the antibiotic response of during chronic lung infection.

Greenwald M, Meinig S, Plott L, Roca C, Higgs M, Vitko N mBio. 2024; 15(6):e0345123.

PMID: 38651896 PMC: 11237767. DOI: 10.1128/mbio.03451-23.

References

Langton Hewer S, Smyth A . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009; (4):CD004197. DOI: 10.1002/14651858.CD004197.pub3. View

Marshall B . Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!. Am J Respir Crit Care Med. 2004; 169(7):781-2. DOI: 10.1164/rccm.2401009. View

Plummer A, Wildman M . Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2011; (1):CD006682. DOI: 10.1002/14651858.CD006682.pub3. View

Flume P, Mogayzel Jr P, Robinson K, Goss C, Rosenblatt R, Kuhn R . Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180(9):802-8. DOI: 10.1164/rccm.200812-1845PP. View

Aaron S, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R . Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol. 2002; 40(11):4172-9. PMC: 139693. DOI: 10.1128/JCM.40.11.4172-4179.2002. View

Smith A, Fiel S, Mayer-Hamblett N, Ramsey B, Burns J . Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003; 123(5):1495-502. DOI: 10.1378/chest.123.5.1495. View

Lee T, Brownlee K, Denton M, Littlewood J, Conway S . Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol. 2004; 37(2):104-10. DOI: 10.1002/ppul.10401. View

Sanders D, Bittner R, Rosenfeld M, Hoffman L, Redding G, Goss C . Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182(5):627-32. PMC: 5450763. DOI: 10.1164/rccm.200909-1421OC. View

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91-100. DOI: 10.1002/ppul.10127. View

10.

Moskowitz S, Foster J, Emerson J, Gibson R, Burns J . Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother. 2005; 56(5):879-86. DOI: 10.1093/jac/dki338. View

11.

Etherington C, Hall M, Conway S, Peckham D, Denton M . Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Antimicrob Chemother. 2007; 61(2):425-7. DOI: 10.1093/jac/dkm481. View

12.

Ratjen F, Munck A, Kho P, Angyalosi G . Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2009; 65(4):286-91. DOI: 10.1136/thx.2009.121657. View

13.

Douglas T, Brennan S, Gard S, Berry L, Gangell C, Stick S . Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2008; 33(2):305-11. DOI: 10.1183/09031936.00043108. View

14.

Aaron S, Vandemheen K, Ferris W, Fergusson D, Tullis E, Haase D . Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005; 366(9484):463-71. DOI: 10.1016/S0140-6736(05)67060-2. View